About Us

By partnering and collaborating with various organizations, we are able to strengthen our drug development operations. We are seeking collaborators to maximize the full potential of our lead candidate and licensing opportunities to complement our current platform. Please send business development inquiries via our Contact Us page.

• GSK

  In March 2023, SCYNEXIS and GSK (LSE/NYSE: GSK) signed an exclusive license agreement, amended in Dec 2023, to commercialize BREXAFEMME® (ibrexafungerp tablets) for vulvovaginal candidiasis (VVC) and recurrent VVC (rVVC) and further develop ibrexafungerp as a potential treatment for life-threatening fungal infections. GSK has the rights to develop ibrexafungerp and commercialize BREXAFEMME in all countries except the greater China region and certain other countries already out-licensed by SCYNEXIS to third parties.

  More information can be found here and here.

• Hansoh Pharma

  In February 2021, we announced a licensing and strategic partnership agreement for ibrexafungerp with Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia, that covers the Greater China region. We received a $10 million upfront payment and are eligible to receive development and commercial milestone payments of up to $112 million, plus low double-digit royalties on net sales.

  More information can be found here.

• Merck

  Ibrexafungerp (formerly SCY-078) was initially discovered at our research facilities and developed as part of a research collaboration with Merck. Subsequently, all worldwide intellectual property, development and commercialization rights were transferred to SCYNEXIS. We are currently developing this product as a novel oral and intravenous (IV) drug for the treatment of multiple serious and often life-threatening fungal infections, invasive candidiasis, invasive aspergillosis and invasive fungal infections.